Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus

Journal of Virology

Volumn 76, Issue 11, 2002, Pages 5315-5325

  Chertova, Elena ^a   Bess Jr , Julian W ^a   Crise, Bruce J ^a   Sowder II, Raymond C ^a   Schaden, Terra M ^a   Hilburn, Joanne M ^a   Hoxie, James A ^a   Benveniste, Raoul E ^a   Lifson, Jeffrey D ^a   Henderson, Louis E ^a   Arthur, Larry O ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 120; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRION; VIRUS ENVELOPE; VIRUS PARTICLE;

ANIMALS; ANTIGENS, CD4; CHO CELLS; CRICETINAE; FREEZING; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; HEATING; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MEMBRANE GLYCOPROTEINS; RETROVIRIDAE PROTEINS; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 0036091692     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.11.5315-5325.2002     Document Type: Article

References (57)

1. Strong association of simian immunodeficiency virus (SIVagm) envelope glycoprotein heterodimers: Possible role in receptor-mediated activation
2. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: A candidate SIV vaccine
3. Characterization of clones of HIV-1-infected HuT 78 cells defective in gag gene processing and of SIV clones producing large amounts of envelope glycoprotein
4. Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations
5. Tightly bound zinc in human immunodeficiency virus type 1, human T-cell leukemia virus type I, and other retroviruses
6. Soluble CD4 and dextran sulfate mediate release of gp120 from HIV-1: Implications for clinical trials
7. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication
8. Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type I virions and microvesicles: Implications for viral pathogenesis and immune regulation
9. N-Butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposure
10. Specific incorporation of cyclophilin A into HIV-1 virions
11. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions
12. The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection
13. Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix
14. Physicochemical dissociation of CD4-mediated syncytium formation and shedding of human immunodeficiency virus type 1 gp120
15. Assembly and morphology of HIV: Potential effect of structure on viral function
16. Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment
17. Enhanced binding of antibodies to neutralization epitopes following thermal and chemical inactivation of human immunodeficiency virus type 1
18. Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120
19. Molecular characterization of gag proteins from simian immunodeficiency virus (SIVMne)
20. Gag precursors of HIV and SIV are cleaved into six proteins found in the mature virions
21. Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses
22. Morphometric analysis of recombinant soluble CD4-mediated release of the envelope glycoprotein gp120 from HIV-1
23. Significance of premature stop codons in env of simian immunodeficiency virus
24. Oligomerization is essential for transport of vesicular stomatitis viral glycoprotein to the cell surface
25. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
26. Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity
27. Biological, molecular, and structural analysis of a cytopathic variant from a molecularly cloned simian immunodeficiency virus
28. Biological, molecular, and structural analysis of a cytopathic variant from a molecularly cloned simian immunodeficiency virus
29. A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells
30. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus
31. Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains
32. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: Effects on infectivity and neutralization
33. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: Correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4
34. Thermodynamic and kinetic analysis of sCD4 binding to HIV-1 virions and of gp120 dissociation
35. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates
36. Dissociation of gp120 from HIV-1 virions induced by soluble CD4
37. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects
38. Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on beta-chemokine and cytokine production in subjects with HIV-1 infection
39. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts
40. Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures
41. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4
42. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR
43. Purification of 120,000 dalton envelope glycoprotein from culture fluids of human immunodeficiency virus (HIV)-infected H9 cells
44. Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients
45. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins
46. Shedding and interspecies type sero-reactivity of the envelope glycopolypeptide gp120 of the human immunodeficiency virus
47. Synthesis, assembly, and processing of viral proteins
48. Folding and oligomerization of influenza hemagglutinin in the ER and the intermediate compartment
49. Functional association of cyclophilin A with HIV-1 virions
50. Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events
51. Mass determination of rous sarcoma virus virions by scanning transmission electron microscopy
52. Assembly and release of SIV env proteins with full-length or truncated cytoplasmic domains
53. Immunogenicity of full-length and truncated SIV envelope proteins
54. Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1
55. Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope
56. The antigenic structure of the HIV gp120 envelope glycoprotein
57. Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases Env incorporation into particles and fusogenicity and infectivity